Ohio is currently home to 3188 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Recruiting
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Register for Updates
Aggressive Driving and Road Rage: A Driving Simulation Experiment.
NCT03430973
Recruiting
Driving a car is the most dangerous behavior most people engage in every day. According to the World Health Organization, about 1.25 million people die each year as a result of road traffic crashes, and they are the leading cause of death among 15 to 29 year olds. According to the National Highway Traffic Safety Administration, 37,461 Americans were killed in motor vehicle crashes in 2016 - about 103 per day. Although there are several causes of traffic crashes (e.g., texting, alcohol consumptio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: The Ohio State University Driving Simulation Laboratory, Columbus, Ohio
Conditions: Aggression
Register for Updates
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Recruiting
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Register for Updates
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Recruiting
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Register for Updates
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
NCT03266627
Recruiting
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Adenovirus, Primary Immune Deficiency Disorder
Register for Updates
Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)
NCT06638879
Recruiting
This study aims to investigate the use of a novel formulation of tacrolimus, as a toothpaste, in a population of patients with oral chronic graft vs. host disease (cGVHD) as an adjunctive therapy in addition to standard-of-care systemic therapy. The investigators plan to summarize our findings to add to the current body of literature regarding managing cGVHD, specifically those with oral involvement. Additionally, establishing effective topical application of tacrolimus in the oral cavity will... Read More
Gender:
ALL
Ages:
Between 1 year and 40 years
Trial Updated:
11/11/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Chronic Graft Versus Host Disease Oral
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Cleveland, Ohio
Conditions: Hypoparathyroidism
Register for Updates
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
NCT05883449
Recruiting
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Register for Updates
Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery
NCT05334485
Recruiting
A double blind, placebo controlled, randomized control trial studying the safety and efficacy of pyridostigmine as a rescue therapy for postoperative ileus. Patients who undergo elective colorectal resection with or without creation of an ostomy, and subsequently develop postoperative ileus will be eligible for enrollment. Patients will be randomized to receive either pyridostigmine or placebo in addition to the current elements of standard of care. Patients will also complete the pyridostigmine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Cleveland Clinic Main Campus, Cleveland, Ohio
Conditions: Postoperative Ileus
Register for Updates
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
NCT05112237
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
11/11/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Cardiomyopathy
Register for Updates
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534
Recruiting
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: NSCLC, Stage I
Register for Updates
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385
Recruiting
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: University of Cincinnati Cancer Center, Cincinnati, Ohio
Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Register for Updates